Tsewang Tashi, MD

Tsewang Tashi, MD, shares data from the PIONEER trial showing that avapritinib increases bone marrow density in patients with indolent systemic mastocytosis.

Tsewang Tashi, MD discusses updated long-term data for avapritinib in indolent systemic mastocytosis from part 3 of the PIONEER trial.

Tsewang Tashi, MD, discusses ​the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.